US NAT yield: where are we after 2 years?
Discussion of very recent literature, calculation of current risk of transfusion transmitted viral infections after introduction of NAT-HCV and NAT-HIV. Determination of cost/benefit of introduction of NAT. Conclusive statement that p24 antigen testing should be omitted after introducztion of
NAT.
NAT.
– Volker Kretschmer
NATA: Network for the advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther heathcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Follow us
Subscribe to our newsletter
- Tutorials
- Resources
- Guides
- Examples
- Docs